Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110020/S045

cobas BRAF V600 Mutation Test

Roche Molecular Systems, Inc. · Decision date Oct 27, 2026

MEDTECHLEDGER EXPLANATIONP110020/S045

What did the FDA decide?

The FDA record identifies this as a 30-day notice supplement, P110020/S045, to the cobas® BRAF V600 Mutation Test PMA, with the stated purpose "to change the manufacturing process for oligonucleotides." The supplement reason is listed as a process change affecting manufacturer, sterilizer, packager or supplier. The record does not name which oligonucleotides are affected or describe the prior or revised process steps.

The identifier shows this notice is a supplement to PMA P110020 rather than an original premarket approval. The decision code OK30 and the 2026-10-27 date are recorded for the notice; the stated purpose alone does not establish safety or clinical effectiveness of the test.

FDA approval order statement

to change the manufacturing process for oligonucleotides
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Pathology
Decision date
Oct 27, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P110020/S045
Regulatory pathway
PMA supplement
Product code
OWD
Decision code
OK30
Decision date
Oct 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Somatic gene mutation detection system.

Product code
OWD
FDA device class
3

For the original device and its historical approval scope, see PMA P110020. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P110020 · Original PMA

    COBAS 4800 BRAF V600 MUTATION TEST

  2. P110020/S045 received

    Application receipt date recorded by FDA.

  3. P110020/S045 · FDA decision

    30-Day Notice

  4. P110020/S046 · Related supplement

    Roche cobas BRAF V600 Mutation Test

Timeline entries are records held by MedtechLedger for P110020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110020

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA approvalAug 17, 2011FDA
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA

Explore the linked device profile

Other records with product code OWD

Product / regulatory recordCompanyPathwayDecision dateSource
RochePMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
RochePMA supplementOct 27, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Roche Molecular System, Inc.PMA supplementOct 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Molecular Systems, Inc.

Headquarters
Not reported
Brand website
roche.com
FDA applicant address
4300 Hacienda Dr., Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records